New model substitute for antibiotics important step in the fight against …



[ad_1]

The Government has commissioned the Public Health Authority to evaluate a new model of antibiotic replacement by 2022. The aim is to ensure the availability of important antibiotics for patients with difficult-to-treat infections with multiresistant bacteria.

"This is a much-anticipated message and a necessary milestone in working together on the management of antibiotic resistance and ensuring access to essential antibiotics in Sweden," says Marie Ohrlander, MSD's Director of Policy and Communication in Sweden. It is not possible to completely prevent the spread of multiresistant bacteria. In order to delay development, it is necessary to collect global energy, where Sweden continues to show the way.

Access to antibiotics is a matter of patient safety and may be crucial for patients suffering from difficult to treat infections with multiresistant bacteria. With our commitment to infectious diseases and problems with antibiotics, we look forward to participating in this pilot study, "says Anders Kärnell, Medical Director of MSD in Sweden.

Fixed compensation in the new model
With the new model the Public Health Authority will evaluate, pharmaceutical companies are committed to delivering, within a given period, a special and medically important type of antibiotic used for patients with certain serious infections caused by multiresistant bacteria. Against this, they receive a fixed annual remuneration. In the pilot study, the Public Health Authority should investigate whether the model is efficient and effective. The task is the result of a collaboration between the Pharmaceutical and Dental Benefits Agency, the TLV and the Public Health Authority, where pharmaceutical companies also had the opportunity to give their opinions and contribute to the design of the model.

Multiresistant Bacteria a Growing Problem
Resistance to antibiotics is a growing social problem that endangers the patient's safety and, at the same time, poses a serious health problem. The prevalence of resistance is increasing in both Sweden and the world. Within the EU, it is estimated that more than 400,000 infections caused by resistant bacteria occur every year and about 33,000 of them cause death. In Sweden, 14,704 cases of antibiotic resistance were reported in 2018.

Resistant bacteria not only endanger the treatment of serious bacterial infections but also rely on effective antibiotics in other procedures such as cancer treatments, transplants and surgeries.

About MSD

Innovations have been our life force for more than 125 years. MSD is a leading global healthcare company that has researched medicines and vaccines against some of the world's most challenging and serious diseases. It is important to us that our innovations are really used and provide people with better health, which is the driving force behind our many commitments in collaboration with academia, health and active social debate. MSD continues its work at the forefront of research to prevent, treat and cure diseases. We focus on cancer, cardiovascular disease, animal diseases, Alzheimer's disease and infectious diseases such as hepatitis C, Ebola and HIV. MSD in Sweden is a subsidiary of Merck & Co. Inc, headquartered in Kenilworth, New Jersey, USA. We are located in 140 countries where we create solutions together with our customers with our prescription drugs, vaccines, biological treatments and veterinary drugs. Do you want to know more about us? Visit www.msd.se, follow us on chirp, LinkedIn, or YouTube.

[ad_2]

Source link